Cancer Clinical Trial -Astex Pharmaceuticals - TAS1553-01

Cancer

Status:

Open

ClinicalTrials.gov:

NCT04637009

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Drug

TAS1553

Phase

Phase I

Condition

Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm

Keywords

Acute Myeloid Leukemia Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm